A
Angeline Bartholomeusz
Researcher at The Chinese University of Hong Kong
Publications - 47
Citations - 4818
Angeline Bartholomeusz is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 33, co-authored 47 publications receiving 4743 citations. Previous affiliations of Angeline Bartholomeusz include Monash University, Clayton campus & Austin Hospital.
Papers
More filters
Journal ArticleDOI
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
Peter W Angus,Rhys Vaughan,Shelly Xiong,Huiling Yang,William E. Delaney,Craig S. Gibbs,Carol L. Brosgart,Danielle Colledge,Rosalind Edwards,Anna Ayres,Angeline Bartholomeusz,Stephen Locarnini +11 more
TL;DR: The development of this novel mutation in the HBV polymerase confers resistance to adefovir dipivoxil, and the patient responded to subsequent lamivudine therapy, achieving normalization of alanine aminotransferase and a significant decrease in serum HBV DNA.
Journal ArticleDOI
Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine
Daniel J. Tenney,Steven Levine,Ronald E. Rose,Ann W. Walsh,S P Weinheimer,Linda Discotto,Mary Jane Plym,Kevin A. Pokornowski,Cheng-Fang Yu,Peter W Angus,A Ayres,Angeline Bartholomeusz,William Sievert,Geoff Thompson,Nadia Warner,Stephen Locarnini,Richard J. Colonno +16 more
TL;DR: Infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TCr HBV background, leading to reduced ETV susceptibility and treatment failure.
Journal ArticleDOI
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
Anna S. Lok,Fabien Zoulim,Stephen Locarnini,Angeline Bartholomeusz,Marc G. Ghany,Jean-Michel Pawlotsky,Yun-Fan Liaw,Masashi Mizokami,Carla Kuiken +8 more
TL;DR: There is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypesic, and clinical resistance to NA therapy.
Journal ArticleDOI
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Julie Sheldon,Nuria Camino,Berta Rodés,Angeline Bartholomeusz,Michael J. Kuiper,Frank Tacke,Marina Núñez,Stefan Mauss,Thomas Lutz,Gerd Klausen,Stephen Locarnini,Vincent Soriano +11 more
TL;DR: The selection of HBV mutations in HBV/HIV-coinfected patients failing TDF therapy is an unlikely event within the first 12 months of treatment, however, HBV from two of the 43 patients treated with TDF for more than 12 months was found to contain one novel mutation located distal to the catalytic site of the HBV pol.
Journal ArticleDOI
HBV drug resistance: mechanisms, detection and interpretation.
TL;DR: The current state of knowledge of HBV resistance to NRTI is attempted, available methods for detecting and quantifying drug resistance are described, and the interpretation of drug resistance and its clinical applications are discussed.